Professor of Medicine
Chief, Division of Gastroenterology in the Department of Medicine
Core Faculty in Innovation & Entrepreneurship
Member in the Duke Clinical Research Institute
Campus mail
03137B Hosp South, Durham, NC 27710
Phone
(919) 684-2052
Email address
andrew.muir@duke.edu
- Hepatitis C
- Primary sclerosing cholangitis
- Cirrhosis
- Liver Transplantation
- Clinical Trials
- Healthcare disparities in liver disease
- Outcomes Research
Education and Training
- Fellow in Gastroenterology, Medicine, Duke University, 1998 - 2000
- Chief Medical Resident, Medicine, Duke University, 1997 - 1998
- Fellow in Gastroenterology, Medicine, Duke University, 1996 - 1997
- Medical Resident, Medicine, Duke University, 1993 - 1996
- M.H.S., Duke University, 2001
- M.D., Duke University, 1993
Grants
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease
- Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
- A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
- RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Quantifying Enteric Metabolism of Branched-chain Amino Acids in Relation to Other Dietary and Microbiota Nutrients
- GS-US-428-4194
- ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
- A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic A
- A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC)
- The Southeastern Liver Health Cohort Study
- CymaBay CB8025-31735